Viral disease

Huntkey Sub-brand OUCICA Won the Outstanding Contribution Award in the Emergency Project of Guangdong Province for the Prevention and Control of New Coronavirus Infection

Tuesday, June 30, 2020 - 2:30pm

In order to fully promote the prevention and control deployment of the epidemic, the Guangdong Provincial Department of Science and Technology leads the "Guangdong Province Special Project on Emergency Response to New Coronavirus Infection Technologies."

Key Points: 
  • In order to fully promote the prevention and control deployment of the epidemic, the Guangdong Provincial Department of Science and Technology leads the "Guangdong Province Special Project on Emergency Response to New Coronavirus Infection Technologies."
  • Huntkey's sub-brand OUCICA was invited to join the topic of "Hospital Infection Prevention and Control Technology Research of New Coronavirus 2.19-nCoV Virus".
  • OUCICA, as a purifier that mainly eliminates bacteria and viruses, is very different from common air purifiers.
  • The most important thing is that it can also destroy the bacterial cell membrane and the protein of the solidified virus.

DGAP-News: Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Tuesday, June 30, 2020 - 2:10pm

[1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.

Key Points: 
  • [1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.
  • As the virus is unable to perform this function by itself, this represents an Achilles heel of virus replication.
  • [3]
    "By targeting the enzyme MEK, an essential component of the signalling cascade, ATR-002 inhibits this pathway and, thus, leads to a blockade of viral replication.
  • This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19.

Enanta Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference

Thursday, June 11, 2020 - 12:02pm

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m.
  • A live webcast will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

Maintaining a Healthy Upper Respiratory Tract Microbiome May Help Prevent Secondary Infections in Influenza A Patients

Tuesday, May 26, 2020 - 6:00pm

Uninfected human patients and ferret URT microbiomes have a stable and similar communities, both within and between individuals, representing a healthy microbiome.

Key Points: 
  • Uninfected human patients and ferret URT microbiomes have a stable and similar communities, both within and between individuals, representing a healthy microbiome.
  • After viral infections clear, the microbiome of the individuals progress towards the healthy microbiome.
  • The complete results, Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection , are published in the journal Nature Communications.
  • Influenza A virus is a highly infectious upper respiratory tract disease in humans and animals caused by a negative-sense segmented RNA virus.

Medical Diagnostic Laboratories, L.L.C., Expands Availability of Coronavirus Disease 2019 (COVID-19) Testing into New York and Increases Testing Capabilities

Tuesday, May 19, 2020 - 1:34pm

This expansion is accompanied by an increase in their capacity for testing, which is available nationwide to hospitals, health systems, organizations, and physicians.

Key Points: 
  • This expansion is accompanied by an increase in their capacity for testing, which is available nationwide to hospitals, health systems, organizations, and physicians.
  • Coronavirus Disease 2019 (COVID-19) is an acute respiratory disease caused by a viral infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • Making diagnostic tools available to health care professionals is crucial for detecting and mitigating the spread of the coronavirus and keeping our communities healthy."
  • MDL is a CLIA-certified, College of American Pathologists (CAP)-accredited infectious disease laboratory specializing in high-complexity, state-of-the-art, automated, high throughput, DNA-based molecular analyses.

Searching the Origin of Novel Coronavirus Needs Global Efforts

Saturday, April 25, 2020 - 1:07am

Like the infectious enveloped virus, such as influenza virus, the novel coronavirus has the characteristics of protease dependence in the infection process of invading infected cells.

Key Points: 
  • Like the infectious enveloped virus, such as influenza virus, the novel coronavirus has the characteristics of protease dependence in the infection process of invading infected cells.
  • Finally, the structural characteristics of the novel coronavirus S protein determine its ability to infect cells and replicate rapidly.
  • Stronger infectivity than influenza virus is the main reason why the novel coronavirus can be pandemic in the world.
  • Virus searching is a very serious scientific issue, which needs to be supported by clear scientific evidence
    Dr. Kitazato Kaio said that coronavirus can be classified into four genera: , , , and .

LoanMart: Staying Safe with COVID-19 in Florida

Friday, April 17, 2020 - 10:00am

Many residents of Florida are particularly concerned since the Southeastern state initially was hit so hard with Coronavirus infections.

Key Points: 
  • Many residents of Florida are particularly concerned since the Southeastern state initially was hit so hard with Coronavirus infections.
  • Alongside other businesses in Florida and throughout the globe, we can be a part of the solution during this critical time.
  • Even the smallest of actions, such as staying home and practicing social distancing can be effective to help reduce the spread of the virus.
  • Keep yourself safe by staying home when you are sick, except to get medical care.

Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19

Friday, March 27, 2020 - 3:40am

This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.

Key Points: 
  • This theranostic approach will use radiopharmaceuticals for detection and diagnosis with the ability to incorporate combination therapies to interrupt the replication of the virus.
  • The company considers that the drug platform will represent a novel theranostic technology which will establish a precision medicine therapeutic intervention that will be inexpensive and lead to more accurate diagnosis, treatment and evaluation of viral infections.
  • Vyripharm believes that this approach may have the potential to be a dominant novel application tool for the early diagnosis, monitoring, evaluation and treatment of coronavirus.
  • Our company recognized that looking at existing drugs that treat related viral infections would provide a timely approach to developing an effective treatment.

Genomics Company Lucence Develops Viral Sample Collection Medical Device for COVID-19 Diagnosis and Surveillance

Friday, March 20, 2020 - 1:00pm

Molecular diagnostics company Lucence announced today the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical device to facilitate more accessible testing of viral infections such as COVID-19.

Key Points: 
  • Molecular diagnostics company Lucence announced today the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical device to facilitate more accessible testing of viral infections such as COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20200320005151/en/
    Genomics Company Lucence Develops Viral Sample Collection Medical Device for COVID-19 Diagnosis and Surveillance (Photo: Business Wire)
    Presently, definitive diagnosis of RNA viral infections such as COVID-19 requires patients with respiratory infections to undergo nose and/or throat swabs, and it is recommended that these samples are transported with chilled media.
  • The SAFER-Sample medical device is a collection kit that comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week.
  • The SAFER-Sample kit has been registered with the Health Sciences Authority (HSA) as a Class A medical device.

Leronlimab Under Evaluation for Potential Treatment of Coronavirus

Tuesday, January 28, 2020 - 1:00pm

Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease.

Key Points: 
  • Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease.
  • Leronlimab could potentially synergize with other retroviral therapies that currently being used for the potential treatment of 2019-nCoV.
  • We look forward to advancing discussions with potential partners to study leronlimab as a treatment option for this deadly virus.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans.